Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC)
Recommend treatment for NMIBC based on risk stratification.
Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies.
Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management.
Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.
The course director will select 6 real cases from his own practice that represent challenging cases in bladder cancer and present them to his panelists. The panelists will review the available literature and formulate a treatment plan based upon the guidelines and published literature. The course director will then present the actual patient outcome and readdress the panelists with follow-up problems and questions to illustrate the many unique aspects of dealing with these patients.